AR and prostate carcinoma: Besides circulating biomarkers, recognizing the distinct genetic features within metastatic prostate cancer, through testing for AR splice variants (AR-Vs) or tumor suppressor genes (TSGs), might also lead to prognostic and predictive biomarkers for precision medicine.